Issue 146 • September 2024

Pharma casts a wide net to hook opportunities in metabolic disorders

The recent success of diabetes and weight loss medications has spurred more interest in other metabolic disorders

Briefing

Eli Lilly boosts sales forecast by $3bn as diabetes and weight loss drugs propel revenue

Feature

Alzheimer’s: drug delivery and the blood brain barrier conundrum

Feature

Era of ADCs: pharma companies innovate to stand out in a buzzing market

Interview

How NVIDIA grew with the healthcare market instead of pushing into it